PDF
(Download)
|
- Turmeric (Curcuma longa)
- Curcumin
- Knee Osteoarthritis
|
Date:
04-15-2014 | HC# 111332-494
|
Re: Curcumin Used with Nonsteroidal Anti-inflammatory Drug Diclofenac Helps Improve Symptoms of Knee Osteoarthritis
Pinsornsak
P, Niempoog S. The efficacy of Curcuma
longa L. extract as an adjuvant therapy in primary knee osteoarthritis: A
randomized control trial. J Med Assoc
Thai. 2012;95(Suppl 1):S51-S58.
In
Thailand, home to these authors, people are living longer, and the incidence of
knee osteoarthritis (OA) is increasing. Medical treatment for knee OA includes
acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs). The prolonged
use of NSAIDs can cause, among other conditions, peptic ulcers and liver and
kidney impairment. Thai traditional medicine offers a safer alternative―curcumin
from turmeric (Curcuma longa)―which
has potent antioxidant, anti-inflammatory, antimicrobial, and anticarcinogenic
properties. Research supports the combined therapy of curcumin and NSAIDs to
increase efficacy and decrease the adverse side effects seen with the use of
NSAIDs alone. These authors conducted a double-blind, prospective, randomized,
control trial from October 2008 to October 2010 to evaluate the efficacy of
curcumin as an adjuvant therapy with the NSAID diclofenac for primary knee OA.
The
authors recruited 88 patients aged between 38 and 80 years who met the
diagnostic criteria for knee OA established by the American College of
Rheumatology. The patients were randomly assigned to take 2 placebo capsules
twice daily and diclofenac (25 mg) 3 times daily for 3 months (group 1; n=44).
In group 2, 44 patients took 2 curcuminoid capsules (250 mg) twice daily and
diclofenac (25 mg) 3 times daily for 3 months. Each curcuminoid capsule
(Government Pharmaceutical Organization; Bangkok, Thailand) contained turmeric
extract equivalent to 250 mg curcuminoids.
To
measure the outcomes, the authors used a pain visual analog scale (VAS) and the
Knee Injury and Osteoarthritis Outcome Score (KOOS) at baseline and after 1, 2,
and 3 months of treatment. KOOS evaluates knee injury and OA in five
categories: symptoms, pain, function in daily living, function in sport and
recreation, and knee-related quality of life.
Of
the original 88 patients, 7 from group 1 and 6 from group 2 dropped out of the
study.
Comparing
the scores on the VAS, the authors discovered that both groups had significant
improvement in pain at the end of the study compared with baseline. The
between-group changes were not significant. Comparing KOOS scores, the authors
report greater symptom improvement in group 2, but comparing the groups in a
repeated analysis of variance (ANOVA) showed no statistical significance. Pain
improvement also tended to be greater in group 2 at 1, 2, and 3 months after
medication, but no statistical significance was seen.
Function
in daily living, which was worse in group 2 at baseline, improved to the same
level as group 1 at months 1 and 2 and was better at the end of the study compared
with baseline (P<0.05), but no statistically significant between-group
changes were seen. Group 1 patients had no statistically significant
improvement compared with baseline. The sport and recreation function showed
sequential improvement in both groups, but, again, no significant between-group
differences were noted. The knee-related quality-of-life score in both groups
was better after medication; no significant between-group differences were
reported.
Overall,
both groups experienced clinical improvement after medication. A greater
improvement in VAS scores was seen in group 2, which implies an additive effect
in pain reduction using curcumin with the NSAID. In the KOOS, when looking at
all 5 aspects, group 2 had superior or equal improvement at the end of the
study.
Among
the adverse effects reported in the control group were renal function
deterioration in 2 patients and facial swelling in 1 patient. In group 2, 1
patient reported hair loss. The authors conclude that the combination therapy
showed a "low complication rate and high safety margin."
The
results are limited by the dropout rate caused by a lack of transportation for
those living in remote areas, as well as the authors' lack of knowledge of the
optimal dose of curcumin for combination therapy with diclofenac. " … In the
near future we hope to use the higher dose of curcumin combination with lower
dose of diclofenac for treatment of osteoarthritis patient to lessen the
gastrointestinal, and renal complications of NSAIDs," they write.
The
authors conclude that the adjuvant therapy of curcumin with diclofenac has a
potential beneficial effect compared with diclofenac alone; however, their
statistical analysis showed no significance.
―Shari Henson
|